STOCKS TELEGRAPH

Tag: IBIO Stock

  • What changed for these 46 stocks in Pre Market Session?

    What changed for these 46 stocks in Pre Market Session?

    Alterity Therapeutics Limited (ATHE) stock plunged -10.31% to $2.0 in the pre-market trading after the company announced the approval of a US patent for the next generation.

    Cinedigm Corp. (NASDAQ: CIDM) shares are trading down -4.55% at $0.525 at the time of writing after it posted Second Quarter Fiscal 2021 Earnings. The company’s 52-week range was noted as $0.25 to $6.00. Analysts have a consensus price target of $3.50.

    iBio Inc. (IBIO) tumbled over -2.34% at $1.67 in pre-market trading today as the Company revealed fiscal first quarter 2021 Financial results and provides a business update.

    CBAK Energy Technology Inc. (CBAT), an Electrical Equipment & Parts company, dropped about -7.4% at $9.01 in pre-market trading Wednesday.

    Comstock Mining Inc. (LODE) stock moved down -1.96 percent to $1.0 in the pre-market trading as it revealed to Host Earnings Call.

    CureVac N.V. (CVAC) lost over -3.01% at $74.19 in pre-market trading Wednesday 18 November 2020 after the news that the Company has established a European-based network to ramp Up manufacturing of its COVID-19 vaccine candidate, CVnCoV.

    Oncternal Therapeutics Inc. (ONCT) is down more than -24.88% at $3.11 in pre-market hours Wednesday 18 November 2020 as the Company increases previously revealed bought deal to $22.5 million. The stock had dropped over -9.41% to $4.14 in the last trading session.

    Before the trading started on 18 November 2020, New Concept Energy Inc. (GBR) is down -11.38% to reach $1.48 after the firm announced its Q3, 2020 results. It has been trading in a 52-week range of $0.55 to $2.19.

    Polar Power Inc. (POLA) stock plunged -7.25% to $3.07 in the pre-market trading. The most recent rating by ROTH Capital, on November 07, 2017, is at a Neutral.

    Trinity Biotech plc (NASDAQ: TRIB) shares are trading down 0.0% at $2.9 at the time of writing. The company’s 52-week range was noted as $0.56 to $3.35 as the company set to Host an Earnings Call.

    So-Young International Inc. (SY) grew over 4.65% at $13.5 in pre-market trading today as the company said it is going to report its earnings to result on November 25, 2020.

    BioNTech SE (BNTX), a Biotechnology company, rose about 4.22% at $90.6 in pre-market trading Wednesday after the report that Pfizer and BioNTech planned to file as vaccine proves 95% effective.

    Sunworks Inc. (SUNW) stock moved down -4.91 percent to $3.68 in the pre-market trading after the Company revealed that the proposed merger with the Peck Company Holdings, Inc. failed to secure stockholder approval.

    Sundial Growers Inc. (SNDL) lost over -3.04% at $0.2424 in pre-market trading Wednesday 18 November 2020 following the announcement of its third-quarter earnings results.

    Tuniu Corporation (TOUR) is up more than 1.04% at $1.95 in pre-market hours Wednesday 18 November 2020. The stock had dropped over -3.98% to $1.93 in the last trading session.

    Before the trading started on 18 November 2020, Taiwan Semiconductor Manufacturing Company Limited (TSM) is up 3.22% to reach $98.79 following the report that Samsung heats up chip wars with the claim that it can catch TSMC by 2022. It has been trading in a 52-week range of $42.70 to $102.44.

    Hill International Inc. (HIL) stock plunged -5.49% to $1.55 in the pre-market trading as the company said that CEO Raouf Ghali and CFO Todd Weintraub are scheduled to present at the following investor conferences during the month of November.

    Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) shares are trading down -4.77% at $0.5615 at the time of writing after the preliminary results following vaccination of non-human primates with TNX-1800 a live attenuated COVID-19 vaccine candidate engineered to express the SARS-CoV-2 spike protein after vaccination. The company’s 52-week range was noted as $0.39 to $2.46. Analysts have a consensus price target of $4.

    Genius Brands International Inc. (GNUS) tumbled over -3.42% at $1.13 in pre-market trading today after the company revealed strategic takeover of ChizComm Ltd. and ChizComm Beacon Media.

    Medley Management Inc. (MDLY), an Asset Management company, rose about 33.73% at $9.0 in pre-market trading Wednesday announced third-quarter earnings results.

    China SXT Pharmaceuticals Inc. (SXTC) stock moved down -3.59 percent to $0.2603 in the pre-market trading.

    Camtek Ltd. (CAMT) lost over -3.64% at $19.05 in pre-market trading Wednesday 18 November 2020 following the news of the commencement of a proposed underwritten public offering of three million ordinary shares.

    Cellectis S.A. (CLLS) is up more than 5.58% at $20.8 in pre-market hours Wednesday 18 November 2020, after the firm announced the appointment of Kyung Nam-Wortman as Cellectis’ Executive Vice President, Chief Human Resources Officer. The stock had dropped over -1.79% to $19.70 in the last trading session.

    Before the trading started on 18 November 2020, TechnipFMC plc (FTI) is up 4.34% to reach $8.42 after the Company received notice to proceed with the EPC contract for Sempra LNG’s and IEnova’s Energía Costa Azul LNG facility. It has been trading in a 52-week range of $4.49 to $21.84.

    Li Auto Inc. (LI) stock soared 3.17% to $36.16 in the pre-market trading after the Company revealed the 3rd quarter of 2020 Earnings results. The most recent rating by Citigroup, on November 16, 2020, is at a Buy.

    BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) shares are trading down -2.47% at $2.76 at the time of writing. The company’s 52-week range was noted as $2.35 to $62.00.

    Neptune Wellness Solutions Inc. (NEPT) tumbled over -2.63% at $1.85 in pre-market trading today after the company posted 2nd quarter loss and missed the predictions.

    Livent Corporation (LTHM), a Specialty Chemicals company, rose about 4.19% at $15.9 in pre-market trading Wednesday following the report of Analysts revised their forecast after disappointing Earnings.

    Micro Focus International plc (MFGP) stock moved up 29.73 percent to $4.8 in the pre-market trading.

    Houghton Mifflin Harcourt Company (HMHC) gained over 5.63% at $3.0 in pre-market trading Wednesday 18 November 2020 after the Company announced financial results for the quarter ended September 30, 2020. The Company revealed its plan to explore the potential sale of HMH Books & Media, its Consumer Publishing business.

    Acasti Pharma Inc. (ACST) is up more than 3.81% at $0.218 in pre-market hours Wednesday 18 November 2020 as the Company offered a business update for Q2, 2020. The stock had jumped over 0.77% to $0.21 in the last trading session.

    Before the trading started on 18 November 2020, Canaan Inc. (CAN) is up 8.73% to reach $3.61. It has been trading in a 52-week range of $1.76 to $13.00.

    VAALCO Energy Inc. (EGY) stock soared 45.1% to $1.48 in pre-market trading.

    Liminal BioSciences Inc. (NASDAQ: LMNL) shares are trading up 11.37% at $4.31 at the time of writing posted third-quarter results. The company’s 52-week range was noted as $3.51 to $31.45.

    Carver Bancorp Inc. (CARV) grew over 3.89% at $6.95 in pre-market trading today.

    Vaxart Inc. (VXRT), a Biotechnology company, dropped about -2.47% at $5.53 in pre-market trading Wednesday after it publicized that it is set to host a Key Opinion Leader (KOL) panel for investors entitled “An Oral Tablet Vaccine – A Potential Global Solution to COVID-19 and Norovirus?” on Thursday, November 19, 2020, at 12pm Eastern Time.

    SCWorx Corp. (WORX) stock moved down -3.64 percent to $1.06 in the pre-market trading.

    Sunoco LP (SUN) lost over -7.0% at $27.11 in pre-market trading Wednesday 18 November 2020 as the Company gained above 5% as Q3 Earnings topped predictions.

    NIO Limited (NIO) is up more than 3.78% at $48.35 in pre-market hours Wednesday 18 November 2020 as the Company revealed its Q3 loss less than expected, whiles sales topped predictions. The stock had jumped over 2.22% to $46.59 in the last trading session.

    Before the trading started on 18 November 2020, Ocugen Inc. (OCGN) is up 4.27% to reach $0.3029 as Company recently revealed Q3 results. It has been trading in a 52-week range of $0.17 to $0.96.

    Weidai Ltd. (WEI) stock soared 9.4% to $1.63 in the pre-market trading after the report that the Company regained compliance after receipt of NYSE Non-compliance letter regarding ADS trading price on October 20, 2020. The most recent rating by Morgan Stanley, on January 21, 2020, is at an Underweight.

    Magnolia Oil & Gas Corporation (NYSE: MGY) shares are trading up 2.99% at $6.2 at the time of writing after the Company missed Earnings predictions. The company’s 52-week range was noted as $3.23 to $13.28.

    Waitr Holdings Inc. (WTRH) grew over 13.68% at $3.24 in pre-market trading today as the Company beat the Earnings outlook.

    Norwegian Cruise Line Holdings Ltd. (NCLH), a Travel Services company, dropped about -6.17% at $20.7 in pre-market trading Wednesday after the company revealed the pricing of 40,000,000 ordinary shares.

    IZEA Worldwide Inc. (IZEA) stock moved up 5.49 percent to $0.77 in the pre-market trading as it revealed Q3 financial results.

    The Boeing Company (BA) gained over 3.53% at $217.46 in pre-market trading Wednesday 18 November 2020 after the report that Boeing’s 737 Max cleared to fly in the US after crashes.

     

  • Here’s Why You Should Avoid iBio (IBIO) Stocks For COVID-19 Vaccine

    Here’s Why You Should Avoid iBio (IBIO) Stocks For COVID-19 Vaccine

    All the companies involved in the production of the coronavirus vaccine, iBio is far behind from its competitors in the vaccine trial. The company has earlier revealed that it has selected IBIO-201, its LicKM-ubunit vaccine, as its leading candidate for the prevention of coronavirus infection. But the company has not provided any promising result related to its coronavirus vaccine candidate nor it entered into the human trial of its vaccine candidate.

    iBio, a biotech innovator and biologics contract manufacturing organization has earlier made the various claims about its vaccine candidate. It has claimed exclusive worldwide license agreement on a cure called ACE2-Fc from Planet  Biotechnology. Not only this, but the company also claimed that its FastPharming system has the ability to produce vaccines quickly using plant cells.

    So, it is better to avoid iBio for the coronavirus vaccine until it catches up and moves its coronavirus vaccine candidate into human trials. Many companies including Moderna, Novavax, AstraZeneca, and Pfizer all are currently in human trials of their vaccine candidate. But iBio, Inc. is still in the lab and far behind from its competitors. To reach the market human trials are necessary.

    Shares of iBio, Inc. (IBIO) traded up 9.30% as it gained +0.20 on Thursday. In the past 52-weeks of trading, this company’s stock has fluctuated between the low range of $0.05 and a high range of $7.45. iBio has moved up 4600.00% from its 52-weeks low and moved down -68.46% from its 52-weeks high. Looking at its profitability, its return on assets and investment is -108.70%, and -57.60%, respectively. If we turn our focus on its liquidity, its current ratio is 1.70. iBio, Inc. market capitalization has remained high, hitting $420.46 million at the time of writing.

    There are various sciences behind iBio stock. If we look at the political stories, Donald Trump is looking for a vaccine before November. Similarly, from a business point of view, billions were given to the companies for the products which are not ready for the market yet. If we turn our focus on iBio, it only claims that it has a vaccine candidate but that is still in the lab.

    It has not advanced it trial to humans which is necessary. iBio stocks soared after it revealed about the FastPharming. But it is not clear yet whether the company has a vaccine or not or it is the trick of the company to excite its stock. So, it is better to avoid the stock of iBio for the coronavirus vaccine until it starts a human trial.

  • Why IBIO Inc [IBIO] is the Best Covid-19 Vaccine Stock to Bet On

    IBIO Inc [NYSE: IBIO] is trading on a monthly support level, and it seems to be holding up quite well. One factor that could trigger a run in this stock is the discovery of a viable COVID-19 vaccine. Yesterday, the company announced that it had settled on its most viable COVID-19 vaccine.

    The company announced that while it had two vaccine candidates named IBIO-200 and IBIO-201, it was going forward with IBIO-201. The company stated that both candidates did well in pre-clinical studies on the production of antibodies for fighting the virus.

    However, it also discovered that IBIO-201 did better in terms of producing more antibodies than IBIO-200, making it a more viable candidate. Nonetheless, the company stated that it would continue pre-clinical development for IBIO-200 and see where it goes.

    Commenting on these developments, CEO Tom Isett stated that the decision to observe the two vaccines together was beneficial as it helped the company to settle on IBIO-201 as the most viable candidate. He added that the company would now go ahead with the toxicology studies on this vaccine candidate and also conduct clinical development on the same. On IBIO-200, the CEO stated that pre-clinical development would go on, and would use it as a potential plug-and-play vaccine system.

    What next for IBIO

    With the company’s vaccine candidate showing potential, the company is in a unique position in the race for a vaccine. That’s because timing will be critical for companies to profit from a COVID-19 vaccine. Companies that will be among the first to release a vaccine are likely to win the majority of the orders. So far, IBIO is among those in the lead for a vaccine.

    A few days ago, the Oxford-led vaccine was paused due to adverse effects on some test subjects. This means that IBIO is still within the right timelines for potential COVID-19 vaccines. If it makes a breakthrough anytime soon, the stock could see an exponential surge in value.

    There is also the fact that the company is small-cap compared to the much bigger companies that are working on a vaccine. This means that if the company’s vaccine is approved, it would have a much bigger leeway for growth compared to companies that already have large market caps. It also means that if it releases a vaccine at the same time as a large-cap, it would have a better chance of exponential gains.

    About IBIO Inc

    IBio is a biotech company that offers manufacturing services for clients and 3rd party companies. It is based in New York, New York.